Chong Kun Dang Pharmaceutical Corporation

Sung Won An

Min Hyo Ki

So Hyun Park

Jin Young Ko

Ji Yeon Kim

Ha Na Yu

Sang Phil Yoon

Ki Seong Ko

Won Kyu Yang

Hye Jung Baik

Sung Bum Jung

Disclosed is a pharmaceutical composition, comprising: a) at least one sorbitan unsaturated fatty acid ester having a polar head with at least two or more &#x2014;OH (hydroxyl) groups; b) at least one phospholipid; c) at least one liquid crystal hardener which is free of an ionizable group and has a triacyl group with 15 to 40 carbon atoms or a carbon ring structure in a hydrophobic moiety; and d) at least one GnRH (gonadotropin-releasing hormone) analogue as a pharmacologically active substance, wherein said lipid pre-concentrate exists as a liquid phase in absence of aqueous fluid and forms into a liquid crystal in presence of aqueous fluid. The pharmaceutical composition is configured to enhance the sustained release of the pharmacologically active substance GnRH analogue.

Sustained-release lipid pre-concentrate of GNRH analogues and pharmaceutical composition comprising the same

Disclosed is a sustained release lipid pre-concentrate, comprising: a) a sorbitan unsaturated fatty acid ester having a polar head with at least two or more &#x2014;OH (hydroxyl) groups; b) a phospholipid; and c) a liquid crystal hardener, free of an ionizable group, having a hydrophobic moiety of 15 to 40 carbon atoms with a triacyl group or a carbon ring structure. The lipid pre-concentrate exists as a liquid phase in the absence of aqueous fluid and forms into a liquid crystal in the presence of aqueous fluid. Also, a pharmaceutical composition further comprising a pharmacologically active ingredient plus the pre-concentrate is provided.

Sustained-release lipid pre-concentrate of pharmacologically active substance and pharmaceutical composition comprising the same

Growing community of inventors

Gyeonggi-do, South Korea

Sung Won An